Compare VTEX & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTEX | KROS |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 561.5M | 584.9M |
| IPO Year | 2019 | 2020 |
| Metric | VTEX | KROS |
|---|---|---|
| Price | $4.01 | $10.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 8 |
| Target Price | $5.97 | ★ $22.25 |
| AVG Volume (30 Days) | ★ 1.2M | 359.4K |
| Earning Date | 01-01-0001 | 06-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 146.00 |
| EPS | N/A | ★ 2.30 |
| Revenue | N/A | ★ $243,864,000.00 |
| Revenue This Year | $12.64 | N/A |
| Revenue Next Year | $10.57 | N/A |
| P/E Ratio | $43.33 | ★ $4.90 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.84 | $9.12 |
| 52 Week High | $6.82 | $22.55 |
| Indicator | VTEX | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 72.84 | 16.71 |
| Support Level | $3.92 | N/A |
| Resistance Level | $4.23 | $15.21 |
| Average True Range (ATR) | 0.18 | 0.73 |
| MACD | 0.10 | -0.28 |
| Stochastic Oscillator | 84.21 | 4.46 |
Vtex provides a software-as-a-service digital commerce platform for enterprise brands and retailers. Its platform enables customers to execute their commerce plan, including building online stores, integrating and managing orders across channels, and creating marketplaces to sell products from third-party vendors. It generates maximum revenues from Brazil followed by Latin America and the rest of the world.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.